Eptifibatide: profile and news

Millennium and Johnson & Johnson Pharmaceutical Research & ...  06 Mar 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving ... - Yahoo! News (press release)

Chairman of Cleveland Clinic Department of Cardiovascular Medicine ...  Feb 9, 2006
He was the first physician to administer recombinant t-PA, 2 different platelet glycoprotein IIb/IIIa inhibitors (abciximab and eptifibatide), and a new ... - International News Service,

Accumetrics Raises $8.25 Million in Series C Financing  Feb 8, 2006
In addition, there is a VerifyNow test for ReoPro(R) (abcimixmab) and Integrilin(R) (eptifibatide), both GP IIb/IIIa inhibitors, which are injectable ... - International News Service,

Thrombolytic Treatment Before Stenting Linked to Increased ...  Feb 14, 2006
...no increase in mortality for patients pre-treated with glycoprotein IIb/IIIa inhibitors such as ReoPro (abciximab), Integrilin (eptifibatide), and Aggrastat ... - MedPage Today,

Millennium Announces New Senior Vice President of Human Resources  09 Feb 2006
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... - PR Newswire (press release),

Accumetrics Raises $8.25 Million in Series C Financing  09 Feb 2006
In addition, there is a VerifyNow test for ReoPro(R) (abcimixmab) and Integrilin(R) (eptifibatide), both GP IIb/IIIa inhibitors, which are injectable ... - PR Newswire (press release),

Millennium Announces Appointments of Executive Vice President of ...  Jan 25, 2006
He joined Millennium in 2004 as the head of sales and marketing for INTEGRILIN® (eptifibatide) Injection, a product the Company sold the development and ... - Yahoo! News (press release)

Millennium Achieves 2005 Financial Guidance  Jan 26, 2006
...revenue of $123.5 million associated with the original collaboration agreement with Schering-Plough Corporation for INTEGRILIN(R) (eptifibatide) Injection. ... - Biotech Intelligence (press release),

Arginox Appoints Robert Terifay as President and Chief Operating ...  Jan 6, 2006
...of the company's commercial presence in the acute care cardiovascular market, taking the company's first product, INTEGRILIN(R) (eptifibatide) Injection to ... - PR Newswire (press release),

New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib ...  11 Dec 2005
...the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving ... - PR Newswire (press release),

The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved ...  Nov 14, 2005
Research of Baltimore today announced that results from a prospective analysis of the CLEAR PLATELETS (Clopidogrel Loading with Eptifibatide to Arrest the ... - PR Newswire (press release),

Early Initiation Of INTEGRILIN(R) (Eptifibatide) for Heart-Attack ...  Nov 12, 2005
Important Safety Information About INTEGRILIN(R) (eptifibatide) Injection in the US INTEGRILIN is indicated for the treatment of patients with acute coronary ... - PR Newswire (press release),

Early Initiation of Integrilin (Eptifibatide) for Heart-Attack ...  Nov 14, 2005
DALLAS, TX -- November 14, 2005 -- Schering-Plough Corporation announced that results from the Time to Integrilin Therapy in Acute Myocardial InfarctioN ... - DG News

Early Initiation Of INTEGRILIN(R) (Eptifibatide) for Heart-Attack ...  Nov 12, 2005
DALLAS, Nov. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that results from the Time to Integrilin Therapy ... - Finanzen.net,

Early Initiation Of INTEGRILIN(R) (Eptifibatide) for Heart-Attack ...  Nov 13, 2005
DALLAS, Nov. 12 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that results from the Time to ... - PR Newswire (press release),

(PRN) - Odimo Incorporated Announces Third Quarter 2005 Results .. ...  Nov 14, 2005
...[+]. (PRN) - Treecon Resources Releases Third Quarter Financial Information. ... [. PRN) - The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved ... - Bolsamania.com,

(PRN) - Governor Perdue Proclaims November 15 SHARE Day ... [+]  Nov 14, 2005
...(PRN) - The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved Superior Reduction in Inflammatory Markers TNF-Alpha and CRP Compared to a Commonly ... - Bolsamania.com,

Pharmacologic cerebral capillary blood flow improvement after deep ...  Sep 14, 2005
Our aim was to improve brain perfusion by reducing platelet plugging with a glycoprotein IIb/IIIa inhibitor (eptifibatide) in an experimental model of deep ... - The Journal of Thoracic and Cardiovascular Surgery

Millennium Initiates Phase II Clinical Trial to Evaluate MLN1202 ...  Aug 18, 2005
...company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a ... - PR Newswire (press release),

Schering-Plough to Acquire From Millennium Exclusive US Marketing ...  Jul 22, 2005
...relevance to customers in this large sector; * More effective and direct control over the management of the US INTEGRILIN® (eptifibatide) INJECTION franchise ... - Yahoo News (press release)

Millennium Reports Second Quarter 2005 Financial Results  Jul 28, 2005
Co-promotion revenue for INTEGRILIN® (eptifibatide) Injection decreased two percent to $47.7 million from $48.7 million in the second quarter of 2004. ... - Yahoo News (press release)

Millennium Pharmaceuticals to Webcast Conference Call on Second ...  Jul 22, 2005
...company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a ... - PharmaLive.com (press release)